Armed with a $48M Se­ries A, Au­ron is look­ing to ap­ply ma­chine learn­ing in can­cer treat­ment

The hype of ma­chine learn­ing has man­aged to bag se­ri­ous cash from in­vestors over the past year, and the lat­est biotech to en­ter the for­ay is look­ing to ap­ply it to can­cer.

Mass­a­chu­setts-based Au­ron Ther­a­peu­tics fo­cus­es on ther­a­pies that tar­get dys­reg­u­lat­ed cells that can lead to tu­mors and can­cer.

Ac­cord­ing to Au­ron CEO and founder Kate Yen, the biotech is de­vel­op­ing ther­a­pies that tar­get dis­rupt­ed cel­lu­lar dif­fer­en­ti­a­tion. To do that it has built a pro­pri­etary ma­chine learn­ing and com­pu­ta­tion­al plat­form dubbed AU­Ri­gin. The plat­form al­lows it to in­te­grate mul­ti omics da­ta sets from both nor­mal hu­man tis­sue and tu­mor sam­ples to help iden­ti­fy path­ways that are crit­i­cal for both nor­mal cel­lu­lar dif­fer­en­ti­a­tion and then how those path­ways have been hi­jacked by tu­mor cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER